Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

References

• American Diabetes AssociationStandards of medical care in diabetes – 2015Diabetes Care201538Suppl 1S1 S9425537700
   PubMed Web of Science ®Google Scholar
• GarberAJAbrahamsonMJBarzilayJIAmerican Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statementEndocr Pract201319Suppl 21 4824129260
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2015381140 14925538310
   PubMed Web of Science ®Google Scholar
• BlondeLRussell-JonesDThe safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studiesDiabetes Obes Metab200911Suppl 326 3419878259
   PubMed Web of Science ®Google Scholar
• GrimmMHanJWeaverCEfficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trialsPostgrad Med2013125347 5723748506
   PubMed Web of Science ®Google Scholar
• TrujilloJMNufferWGLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agentsPharmacotherapy201434111174 118625382096
   PubMed Web of Science ®Google Scholar
• FinemanMFlanaganSTaylorKPharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingClin Pharmacokinet201150165 7421142268
   PubMed Web of Science ®Google Scholar
• NauckMAHolstJJWillmsBSchmiegelWGlucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetesExp Clin Endocrinol Diabetes19971054187 1959285204
   PubMed Web of Science ®Google Scholar
• MacConellLBrownCGurneyKHanJSafety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trialsDiabetes Metab Syndr Obes2012529 4122375098
   PubMedGoogle Scholar
• MontanyaESestiGA review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitusClin Ther200931112472 248820109994
   PubMed Web of Science ®Google Scholar
• BodeBWTestaMAMagwireMPatient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetesDiabetes Obes Metab2010127604 61220590735
   PubMed Web of Science ®Google Scholar
• Bydureon (exenatide extended-release for injectable suspension): US prescribing information (revised May 2014)Wilmington, DE, USAAstraZeneca Pharmaceuticals LP2014
   Google Scholar
• DeYoungMBMacConellLSarinVTrautmannMHerbertPEncapsulation of exenatide in poly-(D,L-lactide-co-glycolide) micro-spheres produced an investigational long-acting once-weekly formulation for type 2 diabetesDiabetes Technol Ther201113111145 115421751887
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240 125018782641
   PubMed Web of Science ®Google Scholar
• BergenstalRMWyshamCMacConellLEfficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialLancet20103769739431 43920580422
   PubMed Web of Science ®Google Scholar
• DiamantMVan GaalLStranksSOnce weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialLancet201037597332234 224320609969
   PubMed Web of Science ®Google Scholar
• Russell-JonesDCuddihyRMHanefeldMEfficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitaglip-tin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDiabetes Care2012352252 25822210563
   PubMed Web of Science ®Google Scholar
• BlevinsTPullmanJMalloyJDURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetesJ Clin Endocrinol Metab20119651301 131021307137
   PubMed Web of Science ®Google Scholar
• BuseJBNauckMForstTExenatide once weekly versus lira-glutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyLancet20133819861117 12423141817
   PubMed Web of Science ®Google Scholar
• InagakiNAtsumiYOuraTSaitoHImaokaTEfficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority studyClin Ther20123491892 190822884767
   PubMed Web of Science ®Google Scholar
• JiLOnishiYAhnCWEfficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitusJ Diabetes Investig20134153 61
   PubMed Web of Science ®Google Scholar
• World Medical AssociationDeclaration of Helsinki: Ethical principles for medical research involving human subjects2008 Available from: http://www.wma.net/en/30publications/10policies/b3/index.htmlAccessed September 25, 2014
   Google Scholar
• BytzerPTalleyNJLeemonMYoungLJJonesMPHorowitzMPrevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adultsArch Intern Med2001161161989 199611525701
   PubMedGoogle Scholar
• IcksAHaastertBRathmannWWarehamNPrevalence of gastrointestinal symptoms in patients with type 2 diabetes: a population-based studyArch Intern Med200216291067 106911996622
   PubMedGoogle Scholar
• KimJHParkHSKoSYDiabetic factors associated with gastrointestinal symptoms in patients with type 2 diabetesWorld J Gastroenterol201016141782 178720380013
   PubMed Web of Science ®Google Scholar
• HorowitzMVilsbollTZdravkovicMHammerMMadsbadSPatient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutideDiabetes Obes Metab2008107593 59618435773
   PubMed Web of Science ®Google Scholar
• AstrupARossnerSVan GaalLEffects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled studyLancet200937497011606 161619853906
   PubMed Web of Science ®Google Scholar
• DavidsonJANikkelCGrimmMExenatide once weekly: opportunities in the primary care settingPostgrad Med2013125368 7823748508
   PubMed Web of Science ®Google Scholar
• KlonoffDCBuseJBNielsenLLExenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurr Med Res Opin2008241275 28618053320
   PubMed Web of Science ®Google Scholar
• BuseJBKlonoffDCNielsenLLMetabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trialsClin Ther2007291139 15317379054
   PubMed Web of Science ®Google Scholar
• BunckMCDiamantMCornerAOne-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialDiabetes Care2009325762 76819196887
   PubMed Web of Science ®Google Scholar
• FinemanMSMaceKFDiamantMClinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatmentDiabetes Obes Metab2012146546 55422236356
   PubMed Web of Science ®Google Scholar
• McCallALCoxDJBrodowsRCreanJJohnsDKovatchevBReduced daily risk of glycemic variability: comparison of exenatide with insulin glargineDiabetes Technol Ther2009116339 34419459761
   PubMed Web of Science ®Google Scholar
• WrightADCullCAMacleodKMHolmanRRHypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73J Diabetes Complications2006206395 40117070446
   PubMed Web of Science ®Google Scholar
• DenkerPSDimarcoPEExenatide (exendin-4)-induced pancreatitis: a case reportDiabetes Care200629247116443920
   PubMed Web of Science ®Google Scholar
• TripathyNRBashaSJainRShettySRamachandranAExenatide and acute pancreatitisJ Assoc Physicians India200856987 98819322980
   PubMedGoogle Scholar
• AyoubWAKumarAANaguibHSTaylorHCExenatide-induced acute pancreatitisEndocr Pract201016180 8319703814
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationInformation for Healthcare Professionals: exenatide (marketed as Byetta)2008 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htmAccessed September 25, 2014
   Google Scholar
• RaschiEPiccinniCPoluzziEMarchesiniGDe PontiFThe association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance databaseActa Diabetol2013504569 57722008948
   PubMed Web of Science ®Google Scholar
• NoelRABraunDKPattersonREBloomgrenGLIncreased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort studyDiabetes Care2009325834 83819208917
   PubMed Web of Science ®Google Scholar
• GirmanCJKouTDCaiBPatients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetesDiabetes Obes Metab2010129766 77120649628
   PubMed Web of Science ®Google Scholar
• GargRChenWPendergrassMAcute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysisDiabetes Care201033112349 235420682680
   PubMed Web of Science ®Google Scholar
• DoreDDSeegerJDArnold ChanKUse of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurr Med Res Opin20092541019 102719278373
   PubMed Web of Science ®Google Scholar
• RomleyJAGoldmanDPSolomonMMcFaddenDPetersALExenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured populationDiabetes Technol Ther20121410904 91122845701
   PubMed Web of Science ®Google Scholar
• SinghSChangHYRichardsTMWeinerJPClarkJMSegalJBGlucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control studyJAMA Intern Med20131737534 53923440284
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationInformation for Healthcare Professionals: acute pancreatitis and sitagliptin (marketed as Januvia and Janumet)2009 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htmAccessed September 25, 2014
   Google Scholar
• BlomgrenKBSundstromASteineckGWiholmBEObesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitisDiabetes Care2002252298 30211815499
   PubMed Web of Science ®Google Scholar
• FimognariFLCorsonelloAPastorellRAntonelli-IncalziRMet-formin-induced pancreatitis: a possible adverse drug effect during acute renal failureDiabetes Care2006295118316644670
   PubMed Web of Science ®Google Scholar
• Gonzalez-PerezASchliengerRGRodriguezLAAcute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort studyDiabetes Care201033122580 258520833867
   PubMed Web of Science ®Google Scholar
• EganAGBlindEDunderKPancreatic safety of incretin-based drugs – FDA and EMA assessmentN Engl J Med20143709794 79724571751
   PubMed Web of Science ®Google Scholar
• CopleyKMcCowenKHilesRNielsenLLYoungAParkesDGInvestigation of exenatide elimination and its in vivo and in vitro degradationCurr Drug Metab200674367 37416724926
   PubMed Web of Science ®Google Scholar
• Ferrer-GarciaJCMartinez-ChanzaNTolosa-TorrensMSanchez-JuanCExenatide and renal failureDiabet Med2010276728 72920546299
   PubMed Web of Science ®Google Scholar
• WeiseWJSivanandyMSBlockCAComiRJExenatide-associated ischemic renal failureDiabetes Care2009322e22 e2319171732
   PubMedGoogle Scholar
• TuttleKRHeilmannCHoogwerfBJBrownCAndersonPWEffects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetesAm J Kidney Dis2013622396 39823684754
   PubMed Web of Science ®Google Scholar
• Bjerre KnudsenLMadsenLWAndersenSGlucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferationEndocrinology201015141473 148620203154
   PubMed Web of Science ®Google Scholar
• BuseJBRosenstockJSestiGLiraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Lancet2009374968339 4719515413
   PubMed Web of Science ®Google Scholar
• GarberAHenryRRatnerRLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialLancet20093739662473 48118819705
   PubMed Web of Science ®Google Scholar
• HegedusLMosesACZdravkovicMLe ThiTDanielsGHGLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutideJ Clin Endocrinol Metab2011963853 86021209033
   PubMed Web of Science ®Google Scholar
• DoreDDSeegerJDChanKAIncidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillanceTher Adv Drug Saf201234157 16425083233
   PubMedGoogle Scholar
• US Department of Health and Human Services Center for Drug Evaluation and ResearchGuidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes2008 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdfAccessed September 25, 2014
   Google Scholar
• ChiltonRJMacConellLAHanJCMarsoSPCharacterization of heart rate increases with glucagon-like peptide-1 agonist therapyCirculation2013128A16290
   Web of Science ®Google Scholar
• RobinsonLEHoltTAReesKRandevaHSO’HareJPEffects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open201331
   Web of Science ®Google Scholar
• MonamiMCremascoFLamannaCGlucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of random-ized clinical trialsExp Diabetes Res2011201121576421584276
   PubMedGoogle Scholar
• GrundySMPasternakRGreenlandPSmithSJrFusterVAssessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of CardiologyCirculation1999100131481 149210500053
   PubMed Web of Science ®Google Scholar
• Russell-JonesDVaagASchmitzOLiraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia200952102046 205519688338
   PubMed Web of Science ®Google Scholar
• BuseJBGarberARosenstockJLiraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trialsJ Clin Endocrinol Metab20119661695 170221450987
   PubMed Web of Science ®Google Scholar
• BuseJMontanyaESestiGFrequency and magnitude of antibody formation are lower with liraglutide than exenatide: LEAD-6 resultsDiabetes Care201059Suppl 1A184
   Google Scholar
• MacConellLPencekRLiYMaggsDPorterLExenatide once weekly: sustained improvement in glycemic control and cardiometa-bolic measures through 3 yearsDiabetes Metab Syndr Obes2013631 4123358123
   PubMedGoogle Scholar
• DiamantMVan GaalLGuerciBExenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trialLancet Diabetes Endocrinol201426464 47324731672
   PubMed Web of Science ®Google Scholar